Oncology News

A novel risk-stratification model developed for noninvasive identification of T1 colorectal cancer may help avoid unnecessary surgeries for high-risk patients.

Individuals preferred stool-based screening for colorectal cancer over colonoscopy, according to survey results published in Cancer Prevention Research.

The FDA granted breakthrough therapy designation to bemarituzumab for use with chemotherapy as first-line treatment of certain patients with gastrointestinal cancers, according to the agent’s manufacturer.

The FDA approved nivolumab as part of combination therapy for certain patients with gastrointestinal malignancies.

Increased use of fecal immunochemical testing correlated with more colorectal cancer screenings and early-stage diagnoses amid the COVID-19 pandemic, according to research in JAMA Network Open.

Low-dose aspirin suppressed the recurrence of colorectal polyps in patients with familial adenomatous polyposis, according to research in The Lancet.

Bristol Myers Squibb announced positive results from its phase 3 CheckMate-648 trial of nivolumab for the treatment of patients with unresectable advanced or metastatic esophageal squamous cell carcinoma.

The diagnostic yield of pancreatic ductal adenocarcinoma was substantial in high-risk mutation carrier but non-existent in mutation-negative proven familial pancreatic cancer kindreds.

Healio Gastroenterology presents the following reports on the most recent research on COVID-19 is gastrointestinal conditions.

Patients who did not comply with colonoscopy, compared with compliers, had more than double the rate of cumulative colorectal cancer mortality during 10 years of follow-up in an organized program, according to study results.